REFERENCES:

Ackland SP et al. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study. J Clin Oncol 2001;19:943-53. Abstract

Alexandre J et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18:562-73. Abstract

Ando M et al. Efficacy of docetaxel 60 mg/m 2 in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 2001;19:336-42. Abstract

Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology 1999;57 Suppl 1:16-20. Abstract

Blum JL et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68. Abstract

Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63. Abstract

Brito RA et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 2001;19:628-33. Abstract

Burstein HJ et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9. Abstract

Conte P et al. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. Oncology (Huntingt) 2001;15:41-3. Abstract

Del Mastro L et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 2001;19:2213-21. Abstract

Esteva FJ et al. Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond. Oncologist 2001;6:133-46. Abstract

Grasselli G, Vigano L, Capri G, et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 2001;19:2222-31. Abstract

Gennari A, Donati S, Danesi R, et al. The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Semin Oncol 2000;27:14-9. Abstract

Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71; discussion 72. Abstract

Hortobagyi GN. Treatment of advanced breast cancer with gemcitabine and vinorelbine. Oncology (Huntingt) 2001;15:15-7. Abstract

Jassem J et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-15. Abstract

Khayat D et al. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2001;19:3367-75. Abstract

Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001;35(2):217-27. Abstract

Kusama M et al. A phase II study of Xeloda™ (capecitabine)in patients with advanced/metastatic breast carcinoma - The Cooperative Study Group of Capecitabine for Breast Carcinoma. Proc ASCO 2001; Abstract 1924.

Meza LA et al. Capecitabine plus paclitaxel as first- or second-line therapy: A multicenter phase II study in metastatic breast cancer. Breast Cancer Res Treat 2001; Abstract 358.

Michaud LB et al. Improved therapeutic index with lower-dose capecitabine in metastatic breast cancer (MBC) patients (Pts). Proc ASCO 2000; Abstract 402.

Miles D et al. Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: Analysis of post-study therapy. Breast Cancer Res Treat 2001; Abstract 442.

Miller KD et al. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2001;15:38-40. Abstract

Nabholtz JM et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001;19:314-21. Abstract

O’Shaughnessy et al. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc ASCO 2000; Abstract 400.

O’Shaughnessy JA et al. Pharmacoeconomic analysis of Xeloda (capecitabine) in combination with docetaxel for the treatment of advanced breast cancer pretreated with anthracylclines. Breast Cancer Res Treat 2001; Abstract 264.

Perez EA et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124-31. Abstract

Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Huntingt) 2001;15:11-4. Abstract

Sledge GW Jr et al. Phase III trial of do xorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An Intergroup trial. Proc ASCO 1997; Abstract 2.

Thuss-Patience PC et al. Capecitabine: A new standard in metastatic breast cancer recurring after anthracycline and taxane-containing chemotherapy? Results of a multicenter phase II trial. Proc ASCO 2001; Abstract 2012.

Tonkin K et al. Preliminary results of a phase I/II study of weekly docetaxel (Taxotere®) combined with intermittent capecitabine (Xeloda®) for patients with anthracycline pre-treated metastatic breast cancer. Proc ASCO 2001; Abstract 2016.

Twelves C et al. Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Cancer Res Treat 2001; Abstract 542.

Valero V et al. Doxorubicin and taxane combination regimens for metastatic breast cancer: Focus on cardiac effects. Semin Oncol 2001;28:15-23. Abstract

Venturini M et al. Dose-finding study of capecitabine in combination with docetaxel and epirubicin in prior untreated,advanced breast cancer patients. Proc ASCO 2000; Abstract 419.

Vukelja SJ et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results. Breast Cancer Res Treat 2001; Abstract 352.

Back | Top of Page